Dosing Order Reversed a CB2 Agonist’s Effect on Morphine Tolerance
O-1966 could worsen or attenuate morphine tolerance in mice depending on administration order. The experiment challenges an unqualified claim that activating CB2 necessarily improves opioid efficacy.
The investigators varied sequence
The synthetic CB2 agonist was administered before, with or after morphine. Hotplate experiments assessed acute antinociception and repeated-treatment adaptation. Separate receptor-binding, signaling and cell assays explored mechanisms.
The unexpected result mattered
Giving O-1966 before or simultaneously with morphine reduced acute antinociception; pretreatment also worsened tolerance. Giving it after morphine preserved the acute response and attenuated tolerance. Favorable findings from one sequence cannot be assigned to the others.
Mechanistic evidence remained incomplete
Experiments suggested interference with opioid-receptor function, but the proposed receptor-dimer explanation did not receive a decisive order-dependent result. Binding at high concentrations also needs distinction from effects at ordinary exposures. The study tested an investigational agonist, not THC or a cannabis product, and did not establish a human dosing sequence. It supports documenting timing carefully rather than turning a receptor label into a universal interaction rule.
Related analysis: Cannabis Tolerance Claims: Questions to Ask Before Relying on Expert Testimony.
Primary research
Modulation of Morphine Analgesia, Antinociceptive Tolerance, and Mu-Opioid Receptor Binding by the Cannabinoid CB2 Receptor Agonist O-1966. Frontiers in pharmacology (2022). DOI: 10.3389/fphar.2022.803331.
